NCT03683914View on ClinicalTrials.gov

Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

September 30, 2018

Primary Completion Date

January 30, 2019

Study Completion Date

February 28, 2019

Conditions

Office Hysteroscopy

Interventions

DRUG

Dinoprostone 3Mg Vaginal Tablet

1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.

DRUG

placebo vaginal tablet

1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.

Trial Locations (1)

11231

Faculty of Medicine Cairo University, Cairo

All Listed Sponsors

lead

Cairo University

OTHER

NCT03683914 - Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients | Biotech Hunter | Biotech Hunter